ROIV

$36.20-$0.08 (-0.22%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$26.1B

722M shares

52-week range

$11.54 – $37.00

97% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change+$26.85

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$67M	+639.0%	$-1.25	$-3.26–$-0.32	—	3
2028	$586M	+772.9%	$-1.05	$-2.73–$-0.27	—	3
2029	$1.7B	+188.5%	$-0.08	$-0.50–$0.56	—	6
2030	$3.3B	+94.5%	$1.56	$0.40–$4.06	23.2×	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.30	$-0.33	-10.1%
2026-05-20	$-0.29	$-0.28	+3.5%
2026-02-06	$-0.30	$-0.24	+19.9%
2025-11-10	$-0.32	$-0.20	+36.9%
2025-08-11	$-0.25	$-0.25	-0.8%
2025-05-29	$-0.26	$-0.29	-10.1%
2025-02-10	$-0.25	$-0.13	+48.6%
2024-11-12	$-0.25

DCF fair valuemodel estimate

Intrinsic value

$2.90

Price

$36.20

Implied downside

-92%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ROIVRoivant Sciences Ltd.	$36.28	+0.33%	$26.2B	—
ASNDAscendis Pharma A/S	$246.23	-3.61%	$15.3B	—
BBIOBridgeBio Pharma, Inc.	$81.21	-3.14%	$15.9B	—
EXASExact Sciences Corporation	$104.91	+0.00%	$20.0B	—
IONSIonis Pharmaceuticals, Inc.	$55.87	-1.17%

Roivant Sciences Ltd. Common Shares

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

www.roivant.com

Employees: 721
IPO / List date: Oct 1, 2021
HQ: LONDON

Held by traders on TradeandTell

No one on the platform currently holds ROIV.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2024-09-30	327,700	$3.8M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ROIV yet.

$ROIV chatter on StockTwits

John@DocPharmBullish23h
$ABUS all I have to say is, don’t tender too low if they do a Dutch auction $10 minimum, if you want out early. I’ll say nope, you’ll never have me lucky charms If you’ve been here long enough, you know $10 is still peanuts to what’s in store $ROIV will use this as a vehicle to increase their % ownership without moving a metaphorical finger IMO. I don’t think they participate in buying any shares until after the tender offer is over. Phase 2b protocol alignment should be complete. Will they have a partner ? 🤔 My money is splitting 0/00 and it will hit green.
View on StockTwits ↗
John@DocPharmBullish1d
@MABA1 respect 🫡 $ROIV and $ABUS are some other gems
View on StockTwits ↗
John@DocPharmBullish1d
$ROIV with this BB too
View on StockTwits ↗
MarketBeat Earnings@EarningsInsiderAug 6
https://www.marketbeat.com/earnings/reports/2026-8-6-roivant-sciences-ltd-stock/ $ROIV Roivant Sciences Earnings Transcript
View on StockTwits ↗
Stocktwits News@StocktwitsNewsAug 6
ROIV Q1 2027 Earnings Summary $ROIV https://stocktwits.com/news/earnings/earnings/roiv-q1-2027-earnings-summary/cZoJvu2RJ7a
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 6
$ROIV Q1 '27 Earnings Results & Recap • Reported GAAP EPS of -$0.26 up 21.21% YoY • Reported revenue of $1.44M down -33.55% YoY
View on StockTwits ↗
Jeff S@sheepmanctAug 6
$ROIV https://investor.roivant.com/news-releases/news-release-details/priovant-announces-first-patients-enrolled-phase-3-study-beacon/
View on StockTwits ↗
Jeff S@sheepmanctAug 6
$ROIV https://investor.roivant.com/news-releases/news-release-details/roivant-reports-financial-results-first-quarter-ended-june-30-2/
View on StockTwits ↗
MIKI@MikiTraderAug 6
$ROIV Indeed.
View on StockTwits ↗
Nuclear_Elvis@Nuclear_ElvisBearishJul 31
$ROIV Even if you are investing for "Book Value" as if investing in a Holding Company, you're overpaying for the Valuation of ROIV. The Price-to-Book ratio is around 5.5 which means - at current stock price, you are paying 5 1/2 times the value of all the Assets on the books for Roivant, right now, even though that does account for the stocks that ROIV holds that you may think are accurately reflected in the stock price - they are not. So ROIV can't have its cake and eat it too. Is it a Holding Company? If so, the Price-to-Book says it is 5.5 times overvalued. Or is it a Bio-Tech company that is intent on selling pharmaceuticals? The Price-To-Sales Ratio (P/S Ratio) and the corresponding Revenue-Per-Employee show that is also not working out so well, with little to no revenue over the years. So in either case, when looking at determining "Fair Value" for ROIV, it is a failure using either lens/data points.
View on StockTwits ↗
Nuclear_Elvis@Nuclear_ElvisBearishJul 31
$ROIV Revenue per Employee: $11,456.31 Do any of you ever check Fundamentals data such as that? Should tell you that what you are invested in, is not selling product, and hasn't since inception sold much of anything, yet the 1-year chart reads like a company growing with steadily increasing sales, beating revenue expectations in the 10-Q. Is it bizarro world over here in Roivant?
View on StockTwits ↗
Jeff S@sheepmanctJul 29
$ROIV if interested… https://investor.roivant.com/sec-filings/sec-filing/ars/0001140361-26-029957 https://investor.roivant.com/node/13386/html
View on StockTwits ↗
Nosh@NoshJul 17
$ROIV 👀
View on StockTwits ↗
Brian Sutcliffe@BiibrianJul 16
$ABUS low dutch offer price would buy back 25% of float making it easier to for $ROIV to but remaining float. CEO is working $ROIV on best ways that they can acquire $ABUS while using settlement money available
View on StockTwits ↗
Jeff S@sheepmanctJul 16
$ROIV https://investor.roivant.com/news-releases/news-release-details/arbutus-initiates-international-patent-infringement-enforcement
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.